Pluristem Therapeutics (PSTI +4.2%) enjoys continued upward momentum after Thursday's news that...

|About: Pluristem Therapeutics, Inc. (PSTI)|By:, SA News Editor

Pluristem Therapeutics (PSTI +4.2%) enjoys continued upward momentum after Thursday's news that it received permission from India's health ministry to proceed with a Phase II clinical trial for the treatment of Buerger's disease. The trial could be followed by a larger multi-national Phase III. Shares popped 10% yesterday on the announcement.